• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philogen to attend Seminar on “Drug Sciences” organized by the University of Basel, March 23, 2022.

by last | Mar 17, 2022 | 2022, Past Events

Dario Neri, co-founder, CEO and CSO, is giving a lecture entitled “From encoded combinatorial libraries to clinical-stage targeted therapeutics”  

Philogen to attend the PEGS Europe 2022 on November 14-16, 2022

by last | Mar 15, 2022 | Past Events

Dario Neri, co-founder, CEO and CSO, is giving a lecture entitled “Antibody-cytokine fusions: emerging clinical data in glioblastoma, sarcoma and dermato-oncology indications”. Please follow the link below for more information PEGS 2022...

Philogen to attend World Federation of Neuro-oncology Societies (WFNOS 2022) Virtual 2022 Annual Meeting on March 24-27, 2022

by last | Mar 15, 2022 | 2022, Past Events

Philogen is presenting a ePoster entitled “A novel tumor-targeting cytokine-based therapy in combination with lomustine displays promising anti-tumor activity against glioblastoma” Please follow the link below for more information WFNOS 2022...

Philogen to attend 12th Annual World ADC 2022 on March 29-31

by last | Mar 15, 2022 | 2022, Past Events

Philogen announces its attendance at the 12th Annual World ADC London 2022. Samuele Cazzamalli, Head of Small Molecule Therapeutics at Philogen, is giving a lecture entitled “Pan-tumoral Small Molecule-Drug Conjugates targeting Fibroblast Activation Protein in...

Philogen to give a lecture at the Institute Cancer Center, Amsterdam on April 5, 2022

by last | Mar 15, 2022 | 2022, Past Events

Dario Neri, co-founder, CEO and CSO, is giving a lecture entitled “Antibody-Cytokine Fusions: from the bench to the clinic”.

Philogen to Attend the AACR Annual Meeting on April 8-13, 2022

by last | Mar 15, 2022 | 2022, Past Events

Philogen announces its attendance at the AACR Annual Meeting on April 8-13, 2022. Aureliano Zana, 3rd year PhD student at Philogen, is presenting an ePoster entitled “Fibroblast Activation Protein triggers release of drug payload from non-internalizing small...
« Older Entries
Next Entries »

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch